Clinical Trials Logo

Clinical Trial Summary

This study measures the proportion of enrolled patients taking the uninterrupted HIV post-exposure prophylaxis Genvoya for four weeks


Clinical Trial Description

This study measures the proportion of enrolled patients taking the uninterrupted HIV post-exposure prophylaxis Elvitegravir/Cobicistat/FTC/Tenofovir alafenamide (E/C/F/TAF) for four Weeks.

Elvitegravir is an HIV-1 integrase strand transfer inhibitor (INSTI). Cobicistat is a selective, mechanism-based inhibitor of cytochrome P450 (CYP) enzymes of the CYP3A subfamily. Emtricitabine is a nucleoside reverse transcriptase inhibitor (NRTI) and nucleoside analogue àf 2'-dexicytidine. Tenofovir alafenamide is a nucleotide reverse transcriptase inhibitor (NtRTI) and phosphonoamidate prodrug of tenofovir (2'-deoxyadenosine monophosphate analogue). ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02998320
Study type Interventional
Source Groupe d'Etude sur le Risque d'Exposition des Soignants aux Agents Infectieux
Contact
Status Completed
Phase Phase 3
Start date March 10, 2017
Completion date September 30, 2018

See also
  Status Clinical Trial Phase
Completed NCT02112201 - The ProGirls Study N/A
Active, not recruiting NCT03664362 - The BSHAPE Intervention Program for Safety and Health of Survivors of Cumulative Trauma N/A
Withdrawn NCT01381146 - Victim Impact Modules for Jail Inmates N/A
Completed NCT01866046 - Rapid HIV Testing and Counseling in High Risk Women in Shelters Phase 1
Active, not recruiting NCT01378936 - Jail-Based Impact of Crime Intervention Phase 2
Active, not recruiting NCT01380977 - Trial of Impact of Crime Group Intervention for Jail Inmates Phase 1/Phase 2
Completed NCT02611362 - A Multilevel Gaming Intervention for Persons on PrEP N/A
Recruiting NCT04718194 - Developing Online Interventions to Reduce Stigma-Related Stress, Sexual Health, and HIV Risk Among Young Chinese MSM N/A